Thomas Ciulla MD PC

Recently co-authored: Real-world outcomes (~50,000 eyes) of anti-VEGF therapy for AMD – only 1 letter gained at 1 year, meaningfully worse than clinical trials. Download: https://lnkd.in/efPCAD5 https://www.sciencedirect.com/science/article/pii/S2468653019302805?via%3Dihub Visual Acuity Outcomes and Anti–Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World […]

The 2017 U.S. FDA approval of the first gene therapy for a genetic disease launched a promising new cycle of innovation in ophthalmic therapies…. https://www.youtube.com/watch?v=FNUUnJgWHUY&t= Watch the Advancements in Genetic and Regenerative Therapies panel at Ophthalmology Innovation Summit @ ASRS 2019. REGISTER for our next […]

Just co-authored a comprehensive review, “Innovative Therapies for Neovascular Age-Related Macular Degeneration”… https://lnkd.in/e4P5Z3W Innovative therapies for neovascular age-related macular degeneration (2019). Innovative therapies for neovascular age-related macular degeneration. Expert Opinion on Pharmacotherapy. Ahead of Print. Return to main website.

Recently authored “Introduction to Gene Therapy”, a brief primer, in Ophthalmology Management’s “Revolution in Retina” issue… Ophthalmology Management – Introduction to gene therapy New gene therapy research could result in treatments for chronic disorders of the retina, including neovascular AMD, geographic atrophy, uveitis and more. […]

Recently co-authored the first study to report HRQL weights (utilities) for health states in inherited retinal dystrophy patients, corroborating substantial impact of vision loss on HRQL. https://lnkd.in/e9mcYJ2 Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene […]

In our “real world” study of 49,485 “wet” AMD patient-eyes treated with anti-VEGF agents, visual acuity improved by only 1 letter at 1 year! Outcomes fall far short of randomized clinical trial results. New therapies are needed. Retinal Physician – “Real-World” Outcomes of Anti-VEGF Therapy […]

Just published, “Gene Therapy Implications for Retina Specialists: Evolving endpoints, novel orphan disease treatment paradigms, and the dawn of precision medicine.” The approval and launch of Spark’s LUXTURNA (voretigene neparvovec-ryzl), the first FDA-approved gene therapy for a genetic disease, introduces novel paradigms to clinical practice, […]